ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

New target for anti-inflammatory agents

Study shows that caspases are secondary targets for nonsteroidal anti-inflammatory drugs

by Stu Borman
March 6, 2017 | APPEARED IN VOLUME 95, ISSUE 10

[+]Enlarge
Credit: Cell Chem. Biol.
Computational model of the NSAID fenbufen (green) bound to the active site of caspase-3.
Credit: Cell Chem. Biol.
Computational model of the NSAID fenbufen (green) bound to the active site of caspase-3.

Researchers have discovered that caspases, enzymes that promote inflammation and cell death, are secondary targets for some nonsteroidal anti-inflammatory drugs (NSAIDs) (CellChem. Biol. 2017, DOI: 10.1016/j.chembi​ol.2017.02.003). NSAIDs such as Advil and aspirin are primarily cyclooxygenase inhibitors but hit other targets as well, causing side effects such as stomach pain, heartburn, and bleeding. The addition of caspases to the list of NSAID targets could aid understanding of the drugs’ anti-inflammatory effects and help lead to the design of new agents with reduced side effects. Hang Hubert Yin and coworkers at the University of Colorado, Boulder, studied NSAID targeting in cells exposed to inflammatory stimuli that boost caspase production. Such conditions have not been widely used before in NSAID studies, the researchers say, even though patients with inflammatory conditions often take NSAIDs. Yin’s group shows that under inflammatory conditions, some NSAIDs bind to a common caspase active-site motif and therefore inhibit several types of caspases. “We are currently working on novel, selective caspase inhibitors, hoping to develop the next generation of anti-inflammation drugs,” Yin says.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment